<DOC>
	<DOCNO>NCT00533507</DOCNO>
	<brief_summary>The purpose study assess immunogenicity term antibody response safety/reactogenicity term solicit unsolicited symptom serious adverse event follow primary vaccination Taiwanese infant pneumococcal conjugate vaccine GSK 1024850A co-administered diphtheria , tetanus , acellular pertussis ( DTPa ) -combined vaccine rotavirus vaccine child first 6 month life .</brief_summary>
	<brief_title>Primary Vaccination Study With Pneumococcal Conjugate Vaccine Healthy Children 6 8 Weeks Age</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject , include 68 week age time first vaccination . Subjects investigator believe parent ( ) /guardian ( ) comply requirement protocol . Written inform consent obtain parent ( ) guardian ( ) subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start one month dose vaccine end 7 day dose 1 dose 2 one month dose 3 . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . A family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , rotavirus and/or Streptococcus pneumoniae ; exception vaccine first dose may give within first two week life accord national recommendation ( e.g . Hepatitis B Bacillus CalmetteGu√©rin ( BCG ) ) . History , intercurrent , diphtheria , tetanus , pertussis , polio , hepatitis B Haemophilus influenzae type b disease . Gastroenteritis within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal ( GI ) tract , intussusception ( IS ) medical condition determine serious investigator . History allergic disease reaction likely exacerbate component vaccine . History neurological disorder seizure . Major congenital defect serious chronic illness . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pneumococcal vaccine .</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Primary vaccination</keyword>
</DOC>